We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Leica Biosystems Launches HistoCore PEGASUS Plus Dual-Retort Tissue Processor in Europe

By LabMedica International staff writers
Posted on 04 May 2022

Leica Biosystems (Nussloch, Germany) has launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. More...

For the first time, the technology will now be available to medium-sized laboratories, enabling them to optimize histopathology workflows.

Mid-sized laboratories will now be able to run multiple protocols in parallel on a single instrument, providing a solution that adapts to their workflow needs, and reduces unnecessary hands-on time. The dual retorts on HistoCore PEGASUS Plus increase capacity by 33% compared to a typical 300-cassette single-retort tissue processor. The HistoCore PEGASUS Plus builds on more than 15 years of experience with the larger HistoCore PELORIS system, and also incorporates Leica’s pioneering integrated track and trace technology, the HistoCore I-Scan. This enables laboratories to capture and store individual cassette information, user interactions, and reagent levels, delivering high confidence in the quality of results.

Labs face problems with tissue processing, creating the need for a solution to under- or over-processing. This occurs when labs have to process both biopsy and large routine tissue specimens in the same processing run. In an ideal scenario, biopsy and larger sample tissues would be processed separately using a protocol specific to the specimen. The HistoCore PEGASUS Plus tissue processor addresses this issue by bringing a scalable workflow solution to all labs of all sizes, ensuring optimal conditions for each tissue type without slowing down the lab. The HistoCore PEGASUS Plus is now available in Europe and where the CE mark is accepted for country-specific registration.

“We understand that labs are under pressure of staff shortages, increased daily throughput, and additional complexities with processing different types and sizes of tissue,” said Christine Munz, Vice President of Core Histology at Leica Biosystems. “Large, high throughput labs have confidence in the power and robust performance of our HistoCore PELORIS tissue processing technology. The new PEGASUS PLUS now brings these benefits to mid-sized labs.”

Related Links:
Leica Biosystems 


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.